https://www.selleckchem.com/
corporated in the risk stratification of these patients as well as in future trials to target specific subgroups of patients. To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of mutant unresectable colorectal liver metastases. From October 2013 to December 2017, patients with mutant unresectable liver-limited metastases from colorectal cancer were randomly assigned to receive mFOLFOX6 plus bevacizumab (arm A) or mFOLFOX6 alone (arm . The resectability of liver metastases was de
Like
Comment
Share
